Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

LivaNova to Present Scientific Data on VNS Therapy for Drug-Resistant Epilepsy at American Epilepsy Society 2021 Annual Meeting: https://mms.businesswire.com/media/20191101005329/en/555341/5/LN-Logo-Main-PANTONE.jpg
LivaNova to Present Scientific Data on VNS Therapy for Drug-Resistant Epilepsy at American Epilepsy Society 2021 Annual Meeting


LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced its participation in the American Epilepsy Society (AES) Annual Meeting taking place December

Orlando Health Forms Joint Venture With Acadia Healthcare to Expand Behavioral Health Services in the Region: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Orlando Health Forms Joint Venture With Acadia Healthcare to Expand Behavioral Health Services in the Region


Orlando Health and Acadia Healthcare Company announced today that they have formed a joint venture designed to enhance and expand behavioral health services in the region.


This press release

Acadia Healthcare Forms Joint Venture With Orlando Health: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Acadia Healthcare Forms Joint Venture With Orlando Health


Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it has formed a joint venture with Orlando Health, one of Central Florida’s premier health systems. With Acadia’s partnership

LivaNova to Present Scientific Data on VNS Therapy for Difficult-to-Treat Depression at 4th International Brain Stimulation Conference: https://mms.businesswire.com/media/20191101005329/en/555341/5/LN-Logo-Main-PANTONE.jpg
LivaNova to Present Scientific Data on VNS Therapy for Difficult-to-Treat Depression at 4th International Brain Stimulation Conference


LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced its participation in the 4th International Brain Stimulation Conference, taking place

DGAP-News: MorphoSys AG: Unternehmenskalender 2022: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: MorphoSys AG: Unternehmenskalender 2022
DGAP-News: MorphoSys AG: Unternehmenskalender 2022
DGAP-News: MorphoSys AG: Unternehmenskalender 2022: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: MorphoSys AG: Unternehmenskalender 2022
DGAP-News: MorphoSys AG: Unternehmenskalender 2022
DGAP-News: MorphoSys AG: Corporate Calendar 2022: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: MorphoSys AG: Corporate Calendar 2022
DGAP-News: MorphoSys AG: Corporate Calendar 2022
DGAP-News: MorphoSys AG: Corporate Calendar 2022: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: MorphoSys AG: Corporate Calendar 2022
DGAP-News: MorphoSys AG: Corporate Calendar 2022
Gerresheimer AG: Gerresheimer begibt erfolgreich Schuldschein - Emission erneut deutlich überzeichnet : http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23715/Gerresheimer_logo.svg.png
Gerresheimer AG: Gerresheimer begibt erfolgreich Schuldschein - Emission erneut deutlich überzeichnet
Gerresheimer AG: Gerresheimer begibt erfolgreich Schuldschein - Emission erneut deutlich überzeichnet
Gerresheimer AG: Gerresheimer successfully issues promissory loan - transaction again significantly oversubscribed: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23715/Gerresheimer_logo.svg.png
Gerresheimer AG: Gerresheimer successfully issues promissory loan - transaction again significantly oversubscribed
Gerresheimer AG: Gerresheimer successfully issues promissory loan - transaction again significantly oversubscribed
Entdecke das Naturwunder: Egmont Honey Manuka Honig MGO 829+ UMF 20+ zum unschlagbaren Preis!: https://m.media-amazon.com/images/I/71gEQ4ThahL._SL1500_.jpg
Entdecke das Naturwunder: Egmont Honey Manuka Honig MGO 829+ UMF 20+ zum unschlagbaren Preis!
Entdecke das Naturwunder: Egmont Honey Manuka Honig MGO 829+ UMF 20+ zum unschlagbaren Preis! Jetzt ansehen In der Welt der Naturprodukte gibt es wahre Schätze – und einer davon ist der
Entdecke die Luftfahrt neu: DJI Avata Explorer Combo jetzt zum unschlagbaren Angebot!: https://m.media-amazon.com/images/I/61B-ePmpFWL._AC_SL1500_.jpg
Entdecke die Luftfahrt neu: DJI Avata Explorer Combo jetzt zum unschlagbaren Angebot!
Entdecke die Luftfahrt neu: DJI Avata Explorer Combo jetzt zum unschlagbaren Angebot! Jetzt ansehen Für alle Technikbegeisterten und Luftfahrtabenteurer: Die DJI Avata Explorer Combo setzt neue
HealthEquity Stock: Leading Health Savings Account Investment: https://www.marketbeat.com/logos/articles/med_20240609114559_chart-hqy.jpg
HealthEquity Stock: Leading Health Savings Account Investment

HealthEquity Inc (NASDAQ: HQY) is one of the nation’s largest providers of health savings accounts (HSA) and consumer-directed benefits (CDB) services. Its platform enables individuals to open

Johnson & Johnson is as Cheap as it’s Going to Get: https://www.marketbeat.com/logos/articles/med_20240416075018_chart-jnj-4162024ver001.png
Johnson & Johnson is as Cheap as it’s Going to Get

Shares of Johnson & Johnson (NYSE: JNJ) are as cheap as they will get. The stock is down in premarket trading following the Q1 release, but there is a bottom in play and reality to face. Trading

Med-tech stock Conmed dips ahead of big Q4 report...opportunity?: https://www.marketbeat.com/logos/articles/med_20240129182456_med-tech-stock-conmed-dips-ahead-of-big-q4-report.jpg
Med-tech stock Conmed dips ahead of big Q4 report...opportunity?

When Utica, NY-based medical technology company CONMED Corporation (NYSE:CNMD) reports fourth quarter financials after the close on Wednesday, it is expected to post some of its best growth in

HCA Healthcare Rallies: Weight-loss drugs really a big threat?: https://www.marketbeat.com/logos/articles/med_20240107185912_hca-healthcare-rallies-weight-loss-drugs-really-a.jpg
HCA Healthcare Rallies: Weight-loss drugs really a big threat?

Hospital chain HCA Healthcare, Inc. (NYSE: HCA) has been working on a bullish base and even managed to post gains in a week when the SPDR S&P 500 ETF Trust (NYSEARCA: SPY) pulled back. 

Investors

Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals: https://www.marketbeat.com/logos/articles/med_20231228125224_bristol-myers-squibbs-big-buys-18.jpg
Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals

Bristol Myers Squibb Company (NYSE: BMY) is on a buying spree, announcing two acquisitions in less than a week. 

On December 22, the pharma giant said it was acquiring Karuna Therapeutics Inc.

5 Biotech stocks tapping into unmet mental health treatment needs: https://www.marketbeat.com/logos/articles/med_20231220075859_biotech-stocks-tapping-into-unmet-mental-health-tr.jpg
5 Biotech stocks tapping into unmet mental health treatment needs

Anyone who has dealt with a mental illness or has a loved one who struggles with a mental illness knows how devastating these diseases are. However, a growing number of biotechnology companies are

BellRing Brands gets pumped on the Ozempic weight-loss trend: https://www.marketbeat.com/logos/articles/med_20231126113844_chart-brbr.jpg
BellRing Brands gets pumped on the Ozempic weight-loss trend

Sports nutritional products maker BellRing Brands Inc. (NYSE: BRBR) has seen its stock surge to new all-time highs driven by the popularity of GLP-1 weight-loss medication usage. While the name of

Are the S&P 500's Biggest Q3 Losers Next Year's Winners?: https://www.marketbeat.com/logos/articles/med_20231004081025_are-the-sp-500s-biggest-q3-losers-next-years-winne.jpg
Are the S&P 500's Biggest Q3 Losers Next Year's Winners?

What started out to be a promising third quarter for U.S. stocks turned into a dud. On the backs of artificial intelligence (AI) excitement, the S&P 500 stormed out of the gates in July only to

Could Ely Lilly Be the Best Pharma Stock to Own Now and Forever?: https://www.marketbeat.com/logos/articles/med_20230917134923_chart-lly3.jpg
Could Ely Lilly Be the Best Pharma Stock to Own Now and Forever?

Pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) stock has been on a tear, trading up 57.7% year-to-date (YTD). The company is firing on all cylinders with its leading medications and a highly

Disney's Big Breakup? Wall Street, Iger Ponder A Magical Split: https://www.marketbeat.com/logos/articles/med_20230823072921_disneys-big-breakup-wall-street-iger-ponder-a-magi.jpg
Disney's Big Breakup? Wall Street, Iger Ponder A Magical Split

For Walt Disney Co. (NYSE: DIS) shareholders, their brokerage statements haven’t exactly been the happiest place on earth. The stock has lagged the S&P 500 for the past 10 years, although it’s

Masimo, Medical Device Maker Drops on Q2 Guidance, Opportunity?: https://www.marketbeat.com/logos/articles/med_20230725080758_masimo-medical-device-maker-drops-on-q2-guidance-o.jpg
Masimo, Medical Device Maker Drops on Q2 Guidance, Opportunity?

Shares of health monitoring technology maker Masimo Corporation (NASDAQ: MASI) dropped 24% to $114.30 last week due to a second-quarter performance warning. They are at their lowest level since

Zillow’s Stock Is Hot...The Housing Market Is Not: https://www.marketbeat.com/logos/articles/med_20230714055235_zillows-stock-is-hot.jpg
Zillow’s Stock Is Hot...The Housing Market Is Not

Up more than 70% this year, Zillow Group, Inc. (NASDAQ:ZG) is one of the hottest technology stocks — and yet it's not exactly making a big splash.

In a market focused on artificial intelligence

Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential: https://www.marketbeat.com/logos/articles/med_20230517121722_analysts-say-these-2-mid-cap-biotechs-have-2x-pote.jpg
Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential

On May 15th, mid-cap biotechnology company Sarepta Therapeutics was the big winner in an otherwise quiet day for the Russell 1000 Index. Sarepta jumped more than 30% after an FDA advisory panel